Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia
| Autor: | IR Harrison, JM Clarke, JR Shelton, GT McInnes, RM Perkins |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Adult
Male Prorenoate Potassium medicine.medical_specialty medicine.medical_treatment Spironolactone Pharmacology chemistry.chemical_compound Mineralocorticoid receptor Double-Blind Method Metolazone Canrenone Internal medicine medicine Humans Potency Pharmacology (medical) Diuretics Mineralocorticoid Receptor Antagonists Aldosterone Dose-Response Relationship Drug Endocrinology chemistry Potassium Diuretic Research Article medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 18:169-174 |
| ISSN: | 0306-5251 |
| DOI: | 10.1111/j.1365-2125.1984.tb02449.x |
| Popis: | The plasma potassium responses to the aldosterone antagonists prorenoate K (10 mg/day and 40 mg/day) and spironolactone (25 mg/day and 100 mg/day) were compared following treatment for 11 days in combination with the diuretic metolazone (2.5 mg/day) in a double-blind crossover study in twelve healthy men. The best estimate of the potency of prorenoate K relative to spironolactone in attenuating metolazone induced hypokalaemia was 5.6 with 95% confidence limits 2.4-35.2. The method employed allowed a statistically valid quantitative comparison of the potassium sparing properties of the mineralocorticoid antagonists after repeated doses and may be useful in the preclinical evaluation of these drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text